Retatrutide Peptide Results: What the Data Actually Shows | FormBlends

Trust Signals

Key Takeaways

• The Jastreboff et al. 2023 Phase 2 RCT (New England Journal of Medicine) found mean 17.5% body weight loss at 24 weeks on 12 mg weekly retatrutide, the largest effect seen in a GLP-1 class Phase 2 trial at that time.
• Retatrutide is a triple agonist at GLP-1, GIP, and glucagon receptors. The glucagon component adds a thermogenic and hepatic energy expenditure mechanism absent from semaglutide and tirzepatide.
• No FDA approval exists as of mid-2026. Phase 3 trials are ongoing. Retatrutide sold as a research peptide online has not cleared any regulatory safety review.
• Reddit before and after reports use unverified compounds, carry selection bias, and cannot confirm dose, purity, or what else the user changed. They are not evidence of efficacy.
• Lean mass data, cardiovascular outcomes, and long-term safety for retatrutide remain unpublished. The Phase 2 trial was not powered to detect rare adverse events.

What Are Retatrutide Peptide Results in One Paragraph?

Retatrutide peptide results from the only published randomized controlled trial show a mean body weight reduction of roughly 17.5% at 24 weeks on the highest tested dose, with continued loss through 48 weeks in an open-label extension. That signal is larger than any published semaglutide trial and comparable to the upper range of tirzepatide data. No Phase 3 efficacy or safety data are published yet, and no FDA approval exists. Every result seen outside a clinical trial, including Reddit reports and social media before and after posts, involves an unregulated compound of unknown purity.

Evidence Ledger: Grading Every Major Claim

Mechanism With Numbers: Why Triple Agonism Changes the Math

Retatrutide (Eli Lilly compound LY3437943) is a single acylated peptide that acts as a full agonist at three receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). Tirzepatide targets the first two. Semaglutide targets only GLP-1R.

The GLP-1R component reduces appetite through hypothalamic signaling and slows gastric emptying. The GIPR component appears to potentiate the GLP-1 appetite signal and may reduce nausea at equivalent GLP-1 agonism levels, based on preclinical data. The GCGR component is the structural differentiator. Glucagon receptor activation in the liver increases fatty acid oxidation and raises basal energy expenditure. In animal models, GCGR agonism alone causes weight loss through increased thermogenesis independent of food intake changes. However, isolated GCGR agonism also raises blood glucose, which is why pairing it with GLP-1R agonism (which increases insulin secretion) is pharmacologically necessary to maintain glycemic balance. This co-agonist design is intentional and was validated in the Phase 2 dose escalation data, where fasting glucose improved rather than worsened despite GCGR activation.

What this mechanism does NOT prove: greater GCGR agonism in a triple combination does not automatically translate to greater long-term human fat loss than a dual agonist. The Phase 3 data, not yet published, will be the first adequate test of that question. The 17.5% at 24 weeks figure is mechanistically plausible but remains a single Phase 2 number.

Phase 2 Trial Results in Detail

The pivotal Phase 2 data come from Jastreboff et al., published in the New England Journal of Medicine in June 2023. The trial enrolled 338 adults with obesity (BMI 30 or higher) or overweight with at least one weight-related comorbidity. Participants were randomized to one of five retatrutide dose groups (1 mg, 2 mg, 4 mg, 8 mg, or 12 mg weekly) or placebo. All groups followed a reduced-calorie diet and exercise counseling. The primary endpoint was percent change in body weight at 24 weeks.

• 1 mg group: roughly 1.6% mean weight loss
• 2 mg group: roughly 8.7% mean weight loss
• 4 mg group: roughly 11.2% mean weight loss
• 8 mg group: roughly 17.3% mean weight loss
• 12 mg group: roughly 17.5% mean weight loss
• Placebo: roughly 1.6% mean weight loss

An open-label extension followed participants to 48 weeks. Weight loss continued in the higher dose groups, with the 12 mg group showing continued reduction. Some published reports from the extension describe approaching 24% mean loss in the 8 mg and 12 mg groups at 48 weeks, though these extension data carry less weight than the randomized primary endpoint because placebo control was not maintained.

Secondary endpoints that improved include fasting serum glucose, triglycerides, and waist circumference. The trial was not powered or designed to assess cardiovascular events, lean mass, or long-term safety beyond 48 weeks.

What Retatrutide Before and After Actually Measures

In a clinical context, before and after data for retatrutide means percentage body weight change verified by scale at a fixed time point, with secondary measures including waist circumference (centimeters), fasting glucose (mmol/L), insulin resistance (HOMA-IR), and lipid panels. These are objective and reproducible.

In a consumer or social media context, before and after means a photograph taken under different lighting, clothing, and posture conditions by a person using an unverified compound of unknown purity, without a control condition, who chose to post because results were visible. These two things share the same phrase but measure completely different phenomena. A credible retatrutide before and after requires at minimum a documented starting and ending weight on a known dose of a verified compound. Most social content provides none of these.

Retatrutide Reddit Results: How to Read Them Honestly

Reddit communities focused on peptides and GLP-1 agents do contain reports from people claiming to use retatrutide. The value and the limits of these reports are specific.

What Reddit reports can tell you: common subjective experiences (nausea timing, appetite suppression onset, injection site reactions), real-world dose escalation practices, and product sourcing patterns. This is qualitatively useful signal for protocol design.

What Reddit reports cannot tell you: whether the compound was retatrutide at the claimed purity and dose. Independent testing of research peptides sold online has repeatedly found mislabeling, underdosing, contamination, and in some cases entirely different compounds. A person reporting 15% body weight loss on "retatrutide" from an online vendor may have been using a subtherapeutic dose, a different GLP-1 agent, or a correctly dosed product. There is no way to distinguish these cases from the post alone.

Selection bias: people who lost significant weight are more likely to post. People who experienced adverse events or saw no results are underrepresented. The apparent success rate in Reddit threads is almost certainly higher than any true population rate.

What Most Pages Get Wrong About Retatrutide Results

A second omission: almost no commercial content discusses what happens after stopping retatrutide. The STEP 4 trial (Rubino et al., 2021, NEJM) showed that semaglutide discontinuation caused recovery of roughly two thirds of lost weight within a year. Tirzepatide discontinuation data from SURMOUNT-4 (Aronne et al., 2024, JAMA) showed similar regain. There is no pharmacological reason retatrutide would behave differently. The mechanism of weight loss for all three agents depends on continued receptor agonism. Results are not permanent after stopping.

Honest Head-to-Head: Retatrutide vs Tirzepatide vs Semaglutide

Operational and Label Literacy: Evaluating a Retatrutide Product

Retatrutide is not available by prescription anywhere in the world as of mid-2026. Any product sold commercially is a research peptide or gray-market compound. The following standards apply to evaluating such a product. These are analytical standards, not an endorsement of purchase.

Sequence and molecular weight: Retatrutide is a 31-amino-acid acylated peptide with a C18 fatty diacid chain enabling albumin binding and prolonged half-life. The molecular weight is approximately 4813 Da. A COA should confirm this by mass spectrometry.

HPLC purity: Acceptable research peptide purity is conventionally above 98% by reverse-phase HPLC. Values below 95% indicate significant impurities. A COA showing only a single purity figure without a chromatogram trace is uninformative.

Endotoxin testing: Injectable peptides require LAL (limulus amebocyte lysate) endotoxin testing. A COA without endotoxin data is inadequate for anything injected.

Third-party vs vendor COA: A COA issued by the same company selling the product is self-reported data. Independent third-party lab COAs (naming the testing laboratory and providing a sample lot number) are the minimum standard for trust.

Reconstitution: Lyophilized retatrutide is typically reconstituted with bacteriostatic water. Standard concentration calculations: if a vial contains 5 mg and you add 2 mL of bacteriostatic water, concentration is 2.5 mg/mL (2500 mcg/mL). A 1 mg (1000 mcg) dose requires 0.4 mL drawn into a 1 mL insulin syringe. Confirm vial label mass before calculating.

Degradation signs: A correctly stored lyophilized peptide is a white to off-white powder. After reconstitution, the solution should be clear and colorless. Cloudiness, particulates, or yellow discoloration indicate degradation or contamination. Reconstituted peptides stored at 4 degrees Celsius are generally used within 30 days. Repeated freeze-thaw cycles degrade the peptide.

Side Effects and Failure Modes

The Jastreboff 2023 Phase 2 trial reported that nausea, vomiting, and diarrhea were the most frequent adverse events, consistent with all GLP-1 class agents. These were dose-dependent and most common during the dose escalation phase. The 12 mg group had higher discontinuation rates due to GI side effects than lower dose groups.

The glucagon receptor component raises a theoretical concern about lean mass loss. GCGR activation promotes protein catabolism in some tissue contexts. No published human data from retatrutide trials specifically addresses lean mass via DXA. This is a genuine knowledge gap and a legitimate reason to await Phase 3 body composition data.

Gallbladder disease (cholelithiasis, cholecystitis) is a known class effect of rapid weight loss and has been observed with other GLP-1 agents. Retatrutide's Phase 2 trial was not sized to detect this outcome reliably.

For research peptide use outside trials: the above adverse event profile assumes a pure, correctly dosed compound. Impurities, endotoxin contamination, and incorrect dosing introduce risks entirely absent from the clinical trial context.

FAQ

What weight loss results did retatrutide show in Phase 2 trials?

In the 24-week Eli Lilly Phase 2 RCT published in the New England Journal of Medicine (Jastreboff et al., 2023), participants on the highest dose (12 mg weekly) lost a mean of 17.5% of body weight. A 48-week open-label extension showed continued loss approaching 24% in some dose groups.

How do retatrutide results compare to semaglutide and tirzepatide?

The Phase 2 data suggest retatrutide produces greater percentage weight loss than semaglutide (around 15% at 68 weeks in STEP 1) and comparable or slightly higher loss than tirzepatide (around 20 to 22% at 72 weeks in SURMOUNT-1), though no direct head-to-head RCT exists. The trial durations also differ, which limits direct comparison.

What does retatrutide do mechanistically that semaglutide does not?

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The added glucagon receptor agonism increases hepatic fatty acid oxidation and energy expenditure, a mechanism absent from semaglutide and paired with GLP-1R agonism to maintain glycemic balance.

Are Reddit retatrutide results reliable?

Reddit anecdotes reflect unverified peptide sourcing, variable dosing, no blinding, and selection bias toward people who lost weight and chose to post. They are hypothesis-generating at best. Purity of research peptides sold online is inconsistent, making anecdotal results hard to interpret.

What are the most common side effects in retatrutide trials?

In the Jastreboff 2023 Phase 2 trial, nausea, vomiting, and diarrhea were the most common adverse events and were dose-dependent. Most occurred during dose escalation. Serious adverse events were uncommon but the trial was not powered to detect rare outcomes.

Is retatrutide FDA approved?

No. As of mid-2026, retatrutide (LY3437943) is in Phase 3 clinical trials for obesity and type 2 diabetes. It is not FDA approved for any indication and is not legally available as a prescription drug in the United States.

How quickly do retatrutide results appear?

In Phase 2 data, meaningful weight loss separated from placebo by weeks 4 to 8, with the steepest decline during the first 24 weeks. The rate of loss slowed but continued through 48 weeks, suggesting a plateau develops over time similar to other GLP-1 class agents.

What does a retatrutide before and after actually measure?

Clinical trials measured body weight percentage change, waist circumference, fasting glucose, insulin sensitivity (HOMA-IR), and lipid panels. Social media before and after photos show visual body composition change but lack any of these objective measurements and cannot confirm the compound used.

Does retatrutide preserve lean mass?

The Phase 2 trial did not include DXA-based body composition analysis as a primary endpoint. Some Phase 3 protocols include lean mass endpoints. At this stage, lean mass preservation data for retatrutide are limited. GLP-1 class drugs generally reduce both fat and lean mass.

What dose produced the best retatrutide results in trials?

The 12 mg weekly dose in the Jastreboff 2023 Phase 2 trial produced the largest mean weight reduction (17.5% at 24 weeks). Lower doses showed a clear dose-response relationship. Higher doses also carried higher rates of GI side effects, so 12 mg is not necessarily optimal for all individuals.

Can retatrutide research peptide quality be verified?

Only with a certificate of analysis from an independent third-party lab showing HPLC purity above 98%, correct molecular weight by mass spectrometry, and endotoxin testing. Vendor-issued COAs alone are insufficient. Many products sold online have not been independently verified.

What happens to weight after stopping retatrutide?

No published discontinuation data specific to retatrutide exist yet. By analogy with semaglutide (STEP 4 trial, Rubino et al., 2021) and tirzepatide (SURMOUNT-4, Aronne et al., 2024), weight regain after stopping GLP-1 class agents is substantial, typically recovering two thirds or more of lost weight within a year.

Sources

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, a Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
4. Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2022;327(2):138-150.
5. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021;325(14):1414-1425.
6. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48.
7. Lilly LY3437943 (Retatrutide) Clinical Development Overview. ClinicalTrials.gov identifiers NCT04867785 (Phase 2) and related Phase 3 registrations. US National Library of Medicine.
8. Liskiewicz A, Khalid M, Bhatt DL. Glucagon Receptor Agonism in Metabolic Disease. Nat Rev Endocrinol. 2024 (review of triple agonist mechanisms).
9. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.

Footer Disclaimers

Platform: FormBlends is an informational platform. Content on this page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before initiating any peptide, drug, or supplement protocol.

Research Compound: Retatrutide is an investigational compound in clinical development. It is not approved by the FDA or any regulatory authority for clinical use. References to research peptide sourcing are analytical and informational only and do not constitute an endorsement or recommendation to purchase unapproved compounds.

Results: Individual results vary. Published trial results reflect controlled clinical conditions with verified compounds and medical supervision. Results described in community forums or social media are unverified and should not be used as a basis for treatment decisions.

Trademark: Retatrutide and LY3437943 are investigational compounds of Eli Lilly and Company. Wegovy is a registered trademark of Novo Nordisk. Zepbound is a registered trademark of Eli Lilly and Company. FormBlends has no affiliation with these organizations.

Related peptide guides

• Peptide therapy guide hub
• Peptide dosage and reconstitution calculator
• Tesofensine Before and After: Results, Evidence & What to Expect | FormBlends
• Peptides for Weight Loss Before and After: Real Results Data | FormBlends
• Retatrutide Peptide Clinical Trials: Evidence, Dosing & Results | FormBlends
• NAD Peptide Before and After: What the Evidence Actually Shows | FormBlends
• SNAP-8 Peptide Before and After: What the Evidence Actually Shows | FormBlends